Improved Long-Term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab

BACKGROUND & AIMS: Monitoring serum concentrations of tumor necrosis factor antagonists in patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also called therapeutic drug monitoring, is performed either after patient loss of response (reactive drug monitoring) or i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Gastroenterol Hepatol
Autors principals: Papamichael, Konstantinos, Chachu, Karen A., Vajravelu, Ravy, Vaughn, Byron P., Ni, Josephine, Osterman, Mark T., Cheifetz, Adam S.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5605429/
https://ncbi.nlm.nih.gov/pubmed/28365486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2017.03.031
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars